Zynerba Pharmaceuticals Inc (ZYNE)
Zynerba Pharmaceuticals is engaged in pharmaceutically-produced transdermal cannabinoid therapies for neuropsychiatric disorders. Co. is focused on improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome (FXS), autism spectrum disorder (ASD), and 22q11.2 deletion syndrome (22q). Co. is developing Zygel, the pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting treatment of behavioral symptoms of FXS, ASD and 22q.
|
April 18, 2024 12:36 AM Eastern
Hold (2.00 out of 4)
100th percentile
|
|